{"id":1380,"date":"2018-08-26T17:38:46","date_gmt":"2018-08-26T15:38:46","guid":{"rendered":"https:\/\/biologika-register.de\/willkommen-auf-den-seiten-von-rabbit\/einschlusskriterien\/"},"modified":"2018-11-07T11:59:47","modified_gmt":"2018-11-07T10:59:47","slug":"einschlusskriterien","status":"publish","type":"page","link":"https:\/\/biologika-register.de\/en\/rabbit\/information-on-the-study-for-doctors\/einschlusskriterien\/","title":{"rendered":"Inclusion Criteria"},"content":{"rendered":"<ol>\n<li><b>Diagnose von rheumatoider Arthritis<\/b>The diagnosis RA is made by the rheumatologist taking into account the classification criteria of the American College of Rheumatology (ACR).<br \/>\nNot suitable for inclusion in RABBIT are patients with arthritis in the context of another autoimmune disease in the foreground, such as collagenosis or vasculitis.<\/li>\n<li><b>Age of onset of the disease 16 years and older<\/b><\/li>\n<li><b><b>Inclusion in the group of biologics \/ biosimilar \/ JAK inhibitor patients\u00a0 Start of a new therapy or a new therapy cycle with a biologic \/ biosimilar \/ JAK inhibitor approved for RA<\/b><\/b>\n<ul>\n<li>after failure of at least one therapy with a conventional DMARD or<\/li>\n<li>after failure of a previous therapy with a biologic\/biosimilar\/JAK inhibitor<\/li>\n<\/ul>\n<p>Restart of therapy with a biologic\/biosimilar\/JAK inhibitor after at least a three-month therapy break.<\/p>\n<p>Since 01.01.2017, patients who receive Remicade\u00ae can no longer be included in RABBIT. Patients who receive Remicade\u00ae at a follow-up measuring point will continue to be monitored in RABBIT.<\/li>\n<li><b>Inclusion in the control group Start of a new therapy with a conventional DMARD after failure of at least one therapy with a conventional DMARD.<\/b><\/li>\n<\/ol>\n<div class=\"su-spoiler su-spoiler-style-default su-spoiler-icon-plus su-spoiler-closed\" data-scroll-offset=\"0\" data-anchor-in-url=\"no\"><div class=\"su-spoiler-title\" tabindex=\"0\" role=\"button\"><span class=\"su-spoiler-icon\"><\/span>Therapy \/ conventional DMARDs \/1987 ACR Criteria<\/div><div class=\"su-spoiler-content su-u-clearfix su-u-trim\">\n<p>Biologics, biosimilars and JAK inhibitors currently used to enroll patients in RABBIT<\/p>\n<table>\n<tbody>\n<tr>\n<th>BIOLOGIKA<\/th>\n<th>BIOSIMILARS<\/th>\n<th>JAK-INHIBITOREN<\/th>\n<\/tr>\n<tr>\n<td>Cimzia\u00ae (Certolizumab)<br \/>\nEnbrel\u00ae (Etanercept)<br \/>\nHumira\u00ae (Adalimumab)<br \/>\nKevzara\u00ae (Sarilumab)<br \/>\nMabThera\u00ae (Rituximab)<br \/>\nOrencia\u00ae (Abatacept)<br \/>\nRoACTEMRA\u00ae (Tocilizumab)<br \/>\nSimponi\u00ae (Golimumab)<\/td>\n<td>Benepali\u00ae (Etanercept-Biosimilar)<br \/>\nErelzi\u00ae (Etanercept-Biosimilar)<br \/>\nFlixabi\u00ae (Infliximab-Biosimilar)<br \/>\nRemsima\u00ae (Infliximab-Biosimilar)<br \/>\nRixathon\u00ae (Rituximab-Biosimilar)<\/td>\n<td>Olumiant\u00ae (Baricitinib)<br \/>\nXeljanz\u00ae (Tofacitinib)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h4>Examples for conventional DMARDs<\/h4>\n<table>\n<tbody>\n<tr>\n<td>Methotrexat<br \/>\nLeflunomid<br \/>\nSulfasalazin<br \/>\nHydroxychloroquin\/ Chloroquin<br \/>\nAzathioprin<br \/>\nCyclosporin A<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h4>1987 ACR Criteria<\/h4>\n<table>\n<tbody>\n<tr>\n<td>\n<ol>\n<li>morning stiffness in and around joints for at least 60 minutes before maximum improvement<\/li>\n<li>Swelling as a sign of arthritis in at least three of fourteen joints,<\/li>\n<li>objectified by a doctor (metacarpophalangeal joints on both sides, proximal interphalangeal joints, hand, elbow, knee, ankle and metatarsophalangeal joints)<\/li>\n<li>swelling as a sign of arthritis of the proximal interphalangeal, metacarpophalangeal or wrist joints<\/li>\n<li>symmetrical arthritis<\/li>\n<li>Detection of rheumatic nodules<\/li>\n<li>Detection of rheumatoid factors<\/li>\n<li>Radiological detection of erosions and\/or periarticular osteopenia<\/li>\n<\/ol>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Diagnose von rheumatoider ArthritisThe diagnosis RA is made by the rheumatologist taking into account the classification criteria of the American &#8230; <a title=\"Inclusion Criteria\" class=\"read-more\" href=\"https:\/\/biologika-register.de\/en\/rabbit\/information-on-the-study-for-doctors\/einschlusskriterien\/\" aria-label=\"Read more about Inclusion Criteria\">mehr<\/a><\/p>\n","protected":false},"author":7,"featured_media":0,"parent":579,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_crdt_document":"","generate_page_header":"","footnotes":""},"class_list":{"0":"post-1380","1":"page","2":"type-page","3":"status-publish","5":"infinite-scroll-item"},"_links":{"self":[{"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages\/1380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/comments?post=1380"}],"version-history":[{"count":9,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages\/1380\/revisions"}],"predecessor-version":[{"id":2202,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages\/1380\/revisions\/2202"}],"up":[{"embeddable":true,"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/pages\/579"}],"wp:attachment":[{"href":"https:\/\/biologika-register.de\/en\/wp-json\/wp\/v2\/media?parent=1380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}